iclaprim has been researched along with Pneumonia, Bacterial in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corey, GR; Dryden, M; Duncan, LR; File, TM; Flamm, RK; Huang, DB; Torres, A; Wilcox, MH | 1 |
| Dryden, M; Huang, DB | 1 |
| Micek, ST; Neuner, EA; Ritchie, DJ | 1 |
2 review(s) available for iclaprim and Pneumonia, Bacterial
| Article | Year |
|---|---|
Iclaprim, a dihydrofolate reductase inhibitor antibiotic in Phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety.
Topics: Administration, Intravenous; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Folic Acid Antagonists; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pyrimidines; Skin Diseases, Bacterial; Treatment Outcome | 2018 |
New antibiotics for healthcare-associated pneumonia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Ceftaroline; Cephalosporins; Cross Infection; Doripenem; Glycopeptides; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pseudomonas Infections; Pyrimidines; Staphylococcal Infections; Teicoplanin | 2009 |
1 other study(ies) available for iclaprim and Pneumonia, Bacterial
| Article | Year |
|---|---|
The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens.
Topics: Anti-Bacterial Agents; Bacteria; Drug Resistance, Multiple, Bacterial; Folic Acid Antagonists; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pulmonary Surfactants; Pyrimidines | 2018 |